{"id":"micardis-plus-80-12-5","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dizziness"},{"rate":"3-7","effect":"Fatigue"},{"rate":"2-5","effect":"Hyperuricemia"},{"rate":"2-4","effect":"Hypokalemia"},{"rate":"2-5","effect":"Headache"},{"rate":"2-4","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL3694895","moleculeType":"Small molecule","molecularWeight":"349.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Telmisartan blocks angiotensin II type 1 receptors, preventing vasoconstriction and aldosterone release, thereby reducing peripheral vascular resistance and blood pressure. Hydrochlorothiazide acts as a thiazide diuretic that increases sodium and water excretion, reducing blood volume and further lowering blood pressure. The combination provides synergistic antihypertensive effects.","oneSentence":"Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:34:31.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension in patients requiring combination therapy)"}]},"trialDetails":[{"nctId":"NCT06495710","phase":"NA","title":"Arterial Stiffness and Blood Pressure","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-05-01","conditions":"Hypertension, Vascular Stiffness, Aging","enrollment":228},{"nctId":"NCT06282549","phase":"","title":"Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yuhan Corporation","startDate":"2022-06-08","conditions":"Essential Hypertension","enrollment":1219},{"nctId":"NCT02620163","phase":"PHASE3","title":"Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2015-12","conditions":"Hypertension","enrollment":381},{"nctId":"NCT02262780","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-12-01","conditions":"Healthy","enrollment":20},{"nctId":"NCT05040880","phase":"PHASE1","title":"A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2021-07-08","conditions":"Hypertension","enrollment":46},{"nctId":"NCT00421863","phase":"PHASE4","title":"Italian Study on the Cardiovascular Effects of Systolic Blood Pressure Control - CARDIOSIS Study","status":"COMPLETED","sponsor":"Heart Care Foundation","startDate":"2005-02","conditions":"Hypertension","enrollment":1111},{"nctId":"NCT03021265","phase":"","title":"To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-01-20","conditions":"Hypertension","enrollment":676},{"nctId":"NCT00239369","phase":"PHASE3","title":"Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10","conditions":"Hypertension","enrollment":713},{"nctId":"NCT00146341","phase":"PHASE3","title":"Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-04","conditions":"Hypertension","enrollment":345},{"nctId":"NCT00326768","phase":"PHASE3","title":"Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-05","conditions":"Hypertension","enrollment":184},{"nctId":"NCT02129192","phase":"PHASE1","title":"Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT01975246","phase":"PHASE3","title":"Add-on to Micamlo BP Trial","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-11","conditions":"Hypertension","enrollment":309},{"nctId":"NCT00509470","phase":"PHASE4","title":"Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine","status":"COMPLETED","sponsor":"Tokyo University","startDate":"2007-07","conditions":"Essential Hypertension","enrollment":75},{"nctId":"NCT01911780","phase":"PHASE3","title":"Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2013-07","conditions":"Hypertension","enrollment":132},{"nctId":"NCT02262858","phase":"PHASE1","title":"Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-08","conditions":"Healthy","enrollment":68},{"nctId":"NCT02176512","phase":"PHASE1","title":"Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-09","conditions":"Healthy","enrollment":20},{"nctId":"NCT02175355","phase":"PHASE3","title":"Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-10","conditions":"Hypertension","enrollment":1039},{"nctId":"NCT02177422","phase":"PHASE3","title":"Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-06","conditions":"Hypertension","enrollment":489},{"nctId":"NCT02177435","phase":"PHASE3","title":"Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-02","conditions":"Hypertension","enrollment":491},{"nctId":"NCT02177487","phase":"PHASE3","title":"Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-06","conditions":"Hypertension","enrollment":100},{"nctId":"NCT02183701","phase":"PHASE3","title":"Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-04","conditions":"Hypertension","enrollment":715},{"nctId":"NCT02172586","phase":"PHASE4","title":"Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-01","conditions":"Hypertension","enrollment":363},{"nctId":"NCT00936208","phase":"","title":"PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-05","conditions":"Hypertension","enrollment":3184},{"nctId":"NCT01108809","phase":"","title":"Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-04","conditions":"Hypertension","enrollment":295},{"nctId":"NCT00274638","phase":"PHASE4","title":"PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-07","conditions":"Hypertension","enrollment":805},{"nctId":"NCT00257491","phase":"PHASE3","title":"Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":"Hypertension","enrollment":29},{"nctId":"NCT00239538","phase":"PHASE4","title":"SMOOTH - Blood Pressure Control in Diabetic/Obese Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":840},{"nctId":"NCT00240474","phase":"PHASE4","title":"A Comparison of Telmisartan + Hydrochlorothiazide With Amlodipine + Hydrochlorothiazide in the Control of Blood Pressure in Older Patients With Predominantly Systolic Hypertension (ATHOS Study)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-12","conditions":"Hypertension","enrollment":1000},{"nctId":"NCT00904371","phase":"","title":"Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-12","conditions":"Hypertension, Cardiovascular Diseases","enrollment":211},{"nctId":"NCT01198496","phase":"PHASE4","title":"Recurrent Stroke Prevention Clinical Outcome Study","status":"UNKNOWN","sponsor":"Biomedis International Ltd.","startDate":"2010-10","conditions":"Hypertension, Stroke, Blood Pressure","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"BODY TEMPERATURE INCREASED"},{"count":1,"reaction":"CHILLS"},{"count":1,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":1,"reaction":"DELIRIUM"},{"count":1,"reaction":"OVERDOSE"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"SLEEP WALKING"},{"count":1,"reaction":"SUICIDAL IDEATION"}],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Micardis plus 80/12.5","genericName":"Micardis plus 80/12.5","companyName":"Heart Care Foundation","companyId":"heart-care-foundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Micardis Plus combines telmisartan (an angiotensin II receptor blocker) with hydrochlorothiazide (a thiazide diuretic) to lower blood pressure through dual mechanisms of vasodilation and sodium/fluid reduction. Used for Hypertension (essential hypertension in patients requiring combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}